Targeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia
Yan H, Li G, Zhang X, Zhang C, Li M, Qiu Y, Sun W, Dong Y, Li S, Li J. Targeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia. BMC Psychiatry 2024, 24: 355. PMID: 38741058, PMCID: PMC11089724, DOI: 10.1186/s12888-024-05805-0.Peer-Reviewed Original ResearchConceptsPositive and Negative Symptom ScaleDrug-naive patientsLiquid chromatography-mass spectrometryDrug-naive schizophreniaAssociated with sleep disturbancesOrthogonal partial least squares discriminant analysisSleep disturbancePittsburgh Sleep Quality IndexPartial least-squares discriminant analysisMetabolomics-based approachNegative Symptom ScaleChromatography-mass spectrometryCharacteristic metabolitesSchizophreniaSymptom ScaleMethodsPlasma samplesPotential biological mechanismsSleep Quality IndexClinical symptomsGlycerophospholipid metabolismPartial correlation analysisHealthy controlsMetabolomic analysisPatientsBackgroundSleep disturbanceThe relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study
Luo G, Bai F, Qu X, Jing Y, Wang S, Xuekelaiti Z, Yao C, Li M, Li J. The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study. Journal Of Neural Transmission 2024, 131: 385-391. PMID: 38277043, DOI: 10.1007/s00702-024-02748-4.Peer-Reviewed Original ResearchSerum prolactin levelsSchizophrenia patientsCognitive functionProlactin levelsCognitive deficitsHealthy controlsPatients serum prolactin levelsConsensus Cognitive BatterySignificant cognitive deficitsSevere cognitive deficitsCognitive batteryTreatment researchPsychiatric symptomsSchizophreniaCognitionMCCBDeficitsCross-sectional studyProlactinClinical symptomsClinical dataClinical severitySymptomsPatientsSymptomatology